EVALUATION OF IMMUNOMODULATORY EFFECT OF T-AYU-HM PREMIUM IN EXPERIMENTAL ANIMAL MODELS
Abstract
To evaluate the immunomodulatory effect of T-AYU-HM Premium in experimental animal models. Female Wistar rats were divided into four groups in each model and acclimatized under standard conditions. The control group received vehicle (0.5% CMC), the standard group received Levamisole (50 mg/kg), Test-1 group received T-AYU-HM Premium (600 mg/kg), and Test-2 group received T-AYU-HM Premium (1200 mg/kg). The effect of T-AYU-HM Premium as an immunomodulator was studied by evaluating the neutrophil adhesion model, carbon clearance model, cyclophosphamide-induced neutropenia model, and haemagglutinating antibody titer model. The neutrophil adhesion in standard, Test-1, and Test-2 are 55.39%, 23.32%, and 38.06%, respectively. The %reduction of TLC and DLC in standard and both test groups were significant compared to the control group after nylon fiber treatment. The phagocytic index of standard, test-1 and test-2 was found to be 0.01735, 0.01416, and 0.00923, respectively, this indicates that the test drug affects the reticuloendothelial system. A significant decrease in cyclophosphamide-induced neutropenia implies that the cyclophosphamides’ influence on the hemopoietic system is lessened. The percentage reduction in TLC of standard and both test drug groups are 11.12%, 20.66%, and 13.43%, respectively. The %reduction in DLC of standard and both test drug groups were significant compared to a control group. Haemagglutinating antibody (HA) titer test determines the effect of the drug on humoral immunity. Primary HA titer values of standard, test-1 and test-2 were 5.33, 2.66, and 4.50, respectively. Secondary HA titer values of standard, test-1, and test-2 were 13, 7.16, and 11.16, respectively. HA titer value significantly increases in standard and test groups compared to control in both primary and secondary evaluation. In the current study, results show that the T-AYU-HM Premium tablets exhibit Immunomodulatory activity.
Keywords:
T-AYU-HM Premium, Immunomodulatory study, Levamisole, neutrophil adhesion.DOI
https://doi.org/10.25004/IJPSDR.2021.130409References
Panyod S, Ho CT, Sheen LY. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. Journal of traditional and complementary medicine. 2020;10(4): 420-7.doi: 10.1016/j.jtcme.2020.05.004
Anderson HL, Brodsky IE, Mangalmurt i NS. The evolving erythrocyte: red blood cells as modulators of innate immunity. The Journal of Immunology. 2018;201(5): 1343-51.doi: 10.4049/ jimmunol.1800565. PMID: 30127064; PMCID: PMC6108441.
Desai AM, Saraf MN, Desai C, Desai H, Dalal M. Clinical evaluation of T-AYU-HMTM in the management of sickle cell anemia. International Journal of Pharmaceutical Sciences and Research. 2018;9(8):3573- 3578.
Desai A, Desai K, Desai H, Desai C, Desai R. Effectiveness Report of T-AYU-HM Premium and Onion Vaporisation on Corona Positive Sickle Cell Anemia Patients: A Case Study. International Journal of Pharmaceutical Sciences Drug Research. 2021;13(1):99-102. DOI: https://doi.org/10.25004/IJPSDR.2021.130115
CTRI-http://ctri.nic.inCTRI/2020/08/027477
Ross RG, Selvasubramanian S, Jayasundar S. Immunomodulatory activity of Punica granatum in rabbits—a preliminary study. Journal of ethnopharmacology. 2001;78(1):85-7. https://doi.org/10.1016/ S0378-8741(01)00287-2.
Sunila ES, Kuttan G. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine. Journal of ethnopharmacology. 2004; 90(2-3):339-346. doi: 10.1016/j.jep.2003.10.016. PMID: 15013199.
Shivaprasad HN, Kharya MD, Rana AC, Mohan S. Preliminary Immunomodulatory Act ivit ies of the Aqueous Extract of Terminalia chebula. Pharmaceutical Biology. 2006;44(1):32- 34.
Carrasco FR, Schmidt G, Romero AL, Sartoretto JL, Caparroz‐Assef SM, Bersani‐Amado CA, Cuman RK. Immunomodulatory activity of Zingiber officinale Roscoe, Salvia officinalis L. and Syzygium aromaticum L. essential oils: evidence for humor‐and cell‐mediated responses. Journal of Pharmacy and Pharmacology. 2009;61(7): 961-7.doi: 10.1211/jpp/61.07.0017. PMID: 19589240.
Pravansha S, Thippeswamy BS, Veerapur VP. Immunomodulatory and antioxidant effect of Leptadenia reticulata leaf extract in rodents: possible modulation of cell and humoral immune response. Immunopharmacology and immunotoxicology. 2012;34(6): 1010-9. doi:10.3109/08923973.2012.689767.
Nagarathna P, Reena K, Reddy S, and Wesley J. Evaluation of immunomodulatory activity of the flavanoid from Kigelia africana. Indian Journal of Pharmaceutical and Biological Research; 2014; 2(02), 41-48. https://doi.org/10.30750/ijpbr.2.2.8
Ganeshpurkar A, Saluja AK. Experimental animal models used for evaluation of potential immunomodulators: A mini review. Bulletin of Faculty of Pharmacy, Cairo University. 2017;55(2):211-216.
Vogel HG, editor. Drug discovery and evaluation: pharmacological assays; 2nd Edition; Springer New York, 2002 March, pp: 788-820.
Published
Abstract Display: 546 
PDF Downloads: 471 
